uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Heparin coating of the stent graft-effects on platelets, coagulation and complement activation
Uppsala University, Medicinska vetenskapsområdet, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology.
Show others and affiliations
2001 In: Biomaterials, Vol. 22, 349-355 p.Article in journal (Refereed) Published
Place, publisher, year, edition, pages
2001. Vol. 22, 349-355 p.
URN: urn:nbn:se:uu:diva-95968OAI: oai:DiVA.org:uu-95968DiVA: diva2:170365
Available from: 2007-05-25 Created: 2007-05-25Bibliographically approved
In thesis
1. Platelet Activation and Inhibition in Connection with Vascular Stents
Open this publication in new window or tab >>Platelet Activation and Inhibition in Connection with Vascular Stents
2007 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

This thesis describes the Chandler loop, which makes it possible to conduct studies in vitro of molecular and cellular interactions between whole blood and stents. It was possible to monitor activation and inhibition of the cascades systems, leukocytes and platelets by combining different platelet inhibitors and heparin coating of stents. The clinical study was performed on patients with ACS undergoing PCI and stent implantation. In this study platelet activation markers P-selectin, and αIIb/β3 as well as inflammatory markers were followed from baseline during the first 48 hours post-PCI. The same parameters were evaluated in healthy controls for comparison at baseline.

In vitro: The activation of blood in the Chandler loops were more pronounced for unmodified stent grafts than for partially heparin coated stent grafts. Heparin coated stent grafts dreated the same activation as the loops alone. This indicated that the Chandler loop system was a feasible tool for evaluation of blood compability of stents.

Heparin coating of stents significantly reduced TAT, CD11b and platelet activation. The combination of a heparin coated stent and abciximab reduced TAT and contact activation, as compared to abciximab or heparin coating alone.

Heparin coating of stents in combination with AR-C69931MX resulted in a significant reduction in TAT and preservation of the platelet count but had no effect on contact activation.

Clinical study: Abciximab resulted in an almost total inhibition of fibrinogen binding to platelets and persisted throughout the observation period. Clopidogrel effectscould be observed at four hours but was more pronounced at 24 hours.

P-selectin expression did not differ over time between groups, indicating that platelet activation with α-granule secretion was not affected by abciximab treatment.

The hs-CRP, C3a and sC5b-9 levels increased 24 to 48 hours after PCI in patients with ACS. FXIIa-C1inh was reduced in ACS patients receiving abciximab as compared to controls. The elevated bFGF levels at baseline returned to the levels observed in controls four hours after PCI and stent implantation, whereas an increase in VEGF was observed 24 hours post-PCI.

Place, publisher, year, edition, pages
Uppsala: Acta Universitatis Upsaliensis, 2007. 98 p.
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, ISSN 1651-6206 ; 266
Medicine, platelets, inhibition, activation, stents, ACS, Medicin
urn:nbn:se:uu:diva-7918 (URN)978-91-554-6912-2 (ISBN)
Public defence
2007-06-02, Rudbeckssalen, Rudbecklaboratoriet, Akademiska Sjukhuset, Uppsala, 08:45
Available from: 2007-05-25 Created: 2007-05-25Bibliographically approved

Open Access in DiVA

No full text

By organisation
Department of Oncology, Radiology and Clinical Immunology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Total: 143 hits
ReferencesLink to record
Permanent link

Direct link